Release of a Corporate News, transmitted by DGAP – a company of EquityStory AG. For the content of Communication is the issuer / publisher responsible.
—————————————————————————
Vancouver, British Coloumbia, Canada. 1. February 2010. Response Biomedical Corporation (OTCBB: 885,720 TSX: RBM, OTCBB: RPBIF) announced that The company Guangzhou Wondfo Biotech co., Ltd.. (Wondfo) from China produced as an additional partner. Wondfo the Diagnostics company’s products in China and sell it Biomedicals Response strategic presence in this important global market to expand.
‘We have our first partner, O & D Biotech Co., Ltd.. China (O & D) has already seen great success in China. O & D sold our RAMP (R) Brand Products Partnership (co-branding) in the past few years, "said S. Wayne Kay, Chief Executive Officer. ‘In 2009 we achieved a significant share of our Revenue from sales in China. We look forward to the contract with Wondfo . sign Since we are now represented by two strong partners in this region are, we expect that sales in China continue to make an important contribution to our overall revenues. "
‘China is an exciting and growing market and our continued international market expansion is extremely important for our overall strategy. Wondfo is through trade protected cardiac sell products, while the O & D RAMP (R) brand products for the partnership RAMP (R) – and RAMP (R) sells 200 Reader. "
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid diagnostic tests, the spot with its RAMP (R) platform for clinical and environmental applications will be carried out. RAMP (R) represents a new diagnostic model that a high Sensitivity and reliable information in minutes, delivers. It is Ideal for Point-of-care testing (tests directly on the Patients) as well as for laboratory use.
The RAMP (R) System consists of a Reader (desktopartiges Reader) and disposable test cartridges. The system has the potential to Adaptation to more than 250 medical and außermedizinische tests which are currently being made in the laboratory. The RAMP (R) tests in clinical areas are commercially for the determination of acute Heart attacks, congestive heart failure, influenza and RSV (Respiratory syncytial virus to) by our marketing partner Roche and 3M Health Care Available.
On the extra-clinical market, RAMP (R) Tests are currently for the detection of West Nile virus in the environment and offered Applications in the field of Bioverteidigung include the rapid Spot detection of anthrax and smallpox, as well as the toxins ricin and botulinum. Several other product applications are currently being developed.
Response has the CE Marking for its Reader and the reached clinical testing and quality management system under ISO 13485: 2003 and ISO 9001: 2008 registered.
For further information please contact:
Response Biomedical Corporation Bill Wickson, Director, Investor Relations 1781 – 75th Avenue W. Vancouver, BC V6P 6P2 CANADA Tel 001 604 456 6010 Fax 001 604 456 6066 www.responsebio.com
AXINO AG investor & media relations Königstraße 26 70173 Stuttgart Germany Tel +49 (711) 25 35 92-30 Fax +49 (711) 25 35 92-33 www.axino.de
This is a translation of the original English Press release. Is only the original English press release binding. A liability for the accuracy of the translation is excluded.
01.02.2010 Ad-hoc news, financial news and Press releases transmitted by DGAP. Media archive at http://www.dgap-medientreff.de and http://www.dgap.de
Author:
Time:
Monday, February 1st, 2010 at 4:16 pm
Category:
Comments:
You can leave a response, or trackback from your own site.
RSS:
You can follow any responses to this entry through the RSS 2.0 feed.
Navigation:
Leave a Reply
You must be logged in to post a comment.
